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Abstract
Background Although exertional fatigue is directly and
negatively related to skeletal muscle mass and strength, it is
currently unknown if these variables are associated with
cancer-related fatigue (CRF). Therefore, the purpose of this
study was to determine if CRF is associated with measures
of appendicular lean muscle mass and strength in advanced
cancer patients (ACP).
Methods and results Eighty-four patients (48 men, 36
women aged 61.6±13.2 year) newly diagnosed (≤6 months)
with inoperable (Stages III–IV) gastrointestinal or non-
small cell lung cancer participated in this study. All patients
completed the Brief Fatigue Inventory (BFI). Handgrip
(HGS) and quadriceps (QS) strength were assessed using
isometric and isokinetic dynamometry, respectively. Skele-
tal muscle mass index (SMMI) was calculated from the
appendicular lean mass measured via dual-energy X-ray
absorptiometry divided by body height squared. Univariate
analysis showed BFI to be significantly associated with body
mass index, weight loss, anemia, hypoalbuminemia, activity
level, pain, depression, and sarcopenia along with SMMI,
HGS, and QS. HGS (r=−0.34; p=0.018), QS (r=−0.39; p=
0.024), and SMMI (r=−0.60; p<0.001) were negatively
correlated with BFI total scores in men but not in women.
When adjusted for sex, age, diagnosis, survival, along with
the above characteristics, multivariate analyses showed that
BFI scores were negatively associated with HGS (B=−0.90;
95% CI −1.5:−0.3), QS (−0.2; −0.3:−0.01), and SMMI
(−7.5; −13.0:−2.0). There was a significant sex×SMMI
interaction (10.8; 1.2:20.5), where BFI decreased with
increasing SMMI in men, but did not change with SMMI
in women.
Conclusion These results suggest that in ACP, CRF is
related to muscle mass and strength, which may provide
targets for future interventions.
Keywords Fatigue.Cancer.Skeletal muscle mass index.
Strength
1 Introduction
Cancer-related fatigue (CRF) is a highly prevalent and multi-
factorial symptom that is classically defined as “a persistent,
subjective sense of tiredness related to cancer or cancer
treatmentthatinterfereswithusualfunctioning”[1]. Although
the specific etiology of CRF remains largely unknown, it is
frequently associated with a wide variety of psychosocial
factors (e.g., clinical depression, anxiety, and coping with
chronic illness), and exacerbating symptoms (e.g., chronic
pain, dyspnea, insomnia, nausea, and weight loss) [2, 3]a s
well as antineoplastic treatment side effects (e.g., chemo-
therapy, radiotherapy, surgery, and medications) [4]. In
addition, several co-morbid medical conditions and bio-
markers have been correlated with fatigue including anemia
[5], hypoalbuminemia [6], elevated levels of pro-
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(TNF-α) and IL-6 [7]. Many of these factors are inextricably
linked to one another in promoting fatigue. For example,
TNF-α and IL-6 have been shown to inhibit erythropoiesis
resulting in anemia and fatigue. Thus, it is not surprising that
treatment with epoietin-α h a sd e m o n s t r a t e dp o s i t i v er e s u l t s
in alleviating CRF [8] Hypogonadism (low serum testoster-
one) is also associated with CRF [9]. In fact, not only is low
concentration of testosterone a major contributor of fatigue
but it has been included in a list of biomarkers responsible
for cachexia-related weight loss and muscle wasting [10].
Considering what is known about cancer cachexia and
fatigue, it is surprising that a strong relationship between
CRF and muscle mass/strength has yet to be established.
Cancer-related fatigue has been directly related to mid-arm
circumference [11, 12] and skin-fold measurements [13],
but these assessment techniques can only provide a gross
estimate of the two compartments comprising forearm
muscle mass and subcutaneous fat. A more precise and
accurate method of assessment must be done in order to
determine the composition of the specific limb compart-
ments (e.g., lean body mass/fat mass). Once the appendic-
ular lean mass is determined, then more definitive
statements can be made regarding the relationship between
mass and strength and their impact on the severity of CRF.
What is the importance of establishing these relation-
ships? With the advent of novel CRF models linking
behavioral and physiological indices, a reduction in muscle
mass coupled with muscle weakness could be the objective
measures that partially explain the degree of tiredness and
exhaustion experienced by many patients with advanced
cancer [14]. There is a definite link between muscle mass/
strength and fatigue. For instance, various types of physical
activity programs known to improve physical conditioning,
muscle mass, and strength have proven to be beneficial in
relieving CRF. There is evidence for the benefit of aerobic
activity[15, 16] and resistance training [17] in reducing CRF.
Conversely, de-conditioning as a result of prolonged bedrest
reduces muscle mass and strength and leads to chronic
fatigue [18]. Whether muscle mass and strength directly
affect fatigue or are they simply a consequence of the
condition that is causing the fatigue remains to be clarified.
Identifying the potential clinical significance of progres-
sive declines in both upper and lower skeletal muscle mass
and strength is of vital importance especially in fatigued
patients suffering from cancer cachexia [19]. Thus, there is
a growing need to design studies that specifically address
whether an independent relationship exists between CRF
and muscle strength as well as skeletal muscle mass, while
at the same time adjusting for relevant confounding
covariates. To date, we are not aware of any published
report identifying an association between CRF and meas-
ures of overall body strength and the respective skeletal
muscle limb masses in a cohort of advanced cancer
patients. Therefore, the purpose of this study was to
determine whether or not CRF is related to specific
objective measures of appendicular muscle mass (e.g.,
skeletal muscle mass index (SMMI)) as well as upper and
lower body muscle strength in patients with advanced
gastrointestinal and non-small cell lung cancers.
2 Methods
2.1 Patient recruitment
Allpatientswereassessedwithin6monthsofbeingdiagnosed
with inoperable (Stages III–IV) gastrointestinal or non-small
cell lung cancer and recruited between March and November
2007 from the McGill University Health Center. All the
assessments (e.g., body composition, upper and lower body
strength, and BFI) took place at the McGill Nutrition and
Performance Laboratory (MNUPAL). Ethical approval was
obtained from the Institutional Review Board of McGill
University. Informed consent was obtained in writing from all
subjects prior to recruitment. All data was stored in the
MNUPAL Human Cancer Cachexia Database (HCCD).
2.2 Selection of patients and measures from the HCCD
Of the 210 patients in the HCCD available at the time of
analysis, 84 patients (48 men and 36 women) satisfied the
selection criteria for this study. The selection criteria
included having a DXA scan, assessments for isometric
strength of the forearm using handgrip dynamometry,
isokinetic dynamometry of the quadriceps extensors using
the BIODEX, and the completion of the Brief Fatigue
Inventory. No exclusion of patients were made on the basis
of their comorbidities or concurrent medications, but the
information about these two characteristics was accounted
for in our analyses (see below).
All study patients were evaluated for appendicular lean
mass (ALM) using DXA (Lunar Prodigy Advance™ GE
Healthcare, Madison, WI, USA). Subjects were instructed
to fast for 12 h prior to their appointment at MNUPAL and
avoid wearing any metal items on the day of the scan. Any
patient with a pacemaker was excluded from this study. The
total body DXA scan was performed with the subject
positioned in the center of the DXA table, arms and legs
fully extended. All subjects were instructed to remain still
throughout the 6-min scan. The DXA scans were analyzed
using Advance’s enCORE™ 2006 software (GE Health-
care, Madison, WI, USA). The same technician manually
adjusted the separation of regional appendicular body
segments (e.g., arms and legs) for each scan. Using the
skeleton as the reference, the arms were cut at the
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femur.ThesoftwarethenautomaticallycalculatedtheALMin
kilograms.ThismethodofdeterminingALMconformstothat
used by Heymsfield et al. [20]. The SMMI was calculated by
dividing ALM by the height squared (ALM/ht
2).
For isometric handgrip dynamometry, a spring-loaded,
handgrip dynamometer (Jamar®, Sammons Preston,
Bolingbrook, IL, USA) was used to determine isometric force
of the forearm. The grip of the dynamometer was adjusted to
the most comfortable position prior to collecting data on each
patient. With the patient in a seated position, the dominant arm
was flexed at a 90° angle with the wrist as close to 0° as pos-
sible. The non-dominant arm rested beside the body. Isometric
handgrip force was measured three times in succession without
rest, with each trial lasting approximately 3 s. A 3-s isometric
contraction was selected since it was found that peak output
could be obtained during this time without causing adverse side
effects. The mean of three trials was calculated and averaged
for each patient. The patient was given clear instructions when
to start and stop the contraction, and was encouragedduring the
test to squeeze the handgrip as hard as possible. The use of the
spring-loaded dynamometer to measure handgrip force has
b e e ns h o w nt ob ev a l i da n dh i g h l yr e l i a b l e[ 21]a n dh a sb e e n
used in our laboratory [22] and others [23, 24]t om e a s u r e
handgrip strength in cancer patients.
The leg extensor strength of the quadriceps muscle group
was assessed using isokinetic dynamometry (BIODEX
System 3, BIODEX Medical Systems, Shirley, NY, USA).
The subjects were seated in the BIODEX chair at an incline
between80°and90°.Stabilizingstrapswereplacedacrossthe
shoulders and hips. The BIODEX chair was adjusted until the
rotationalaxisofthe kneejoint was alignedwiththe rotational
axis of the BIODEX leg attachment at the level of the lateral
epicondyle of the femur. The leg was then firmly secured to
the extension attachmentslightlyabove the ankle joint. Range
of motion was determined by having the subject extend their
leg as high as possible without experiencing any discomfort
(maximum extension level) and then lowering their leg to
approximately 90° of flexion (maximum flexion level). The
subjects were permitted to use the handlebars on either side of
the BIODEX chair for additionalstability during testing.Prior
to the start of the test, each subject was instructed on the
protocol and given a reminder that they may stop the test at
any time for any reason. The protocol consisted of two sets of
five repetitions at an angular velocity of 60°/s with a 60 s rest
period between sets. Prior to the first set, one to two practice
repetitions were performed at the pre-determined testing
velocity. Subjects were instructed to perform the repetitions
as fastas possible, and to begin when they were ready. During
the test, the instructor counted down the number of repetitions
and constantly encouraged the patient to move as fast as
possible. During the rest interval between sets, the subjects
fully extended and then flexed their leg in order to re-confirm
the original, pre-set range of motion. The greatest peak torque
value obtained from the five repetitions of both sets was
recorded, averaged, and expressed in newton-meters (Nm).
Theuseofisokineticdynamometerstoevaluatestrengthofthe
knee extensors (e.g., quadriceps) has been shown to be valid
and reliable [25] and has been used previously in our
laboratory [21] and others [26, 27]t oo b t a i nl o w e rl i m b
strength measures in patients with advanced cancer.
In the present study, the BFI was used to assess the
severity of subjective fatigue [28]. This single page
questionnaire consists of nine items, with each item having
a numerical rating between 0–10, and a nine-item global
score is calculated. Three items define the severity of fatigue
during normal waking hours using single word descriptors,
while the six other items evaluate fatigue interference or how
fatigue has impaired the patient’s life over the previous 24 h.
Construct validity for the nine items ranged from 0.81 (usual
fatigue) to 0.92 (activity) indicating that all nine items are
representative of a single fatigue factor [28]. The concurrent
validity demonstrated that BFI was significantly and
strongly correlated with the Functional Assessment of
Cancer Therapy-Fatigue and the Profile of Mood States-
Fatigue subscales. Cronbach’s coefficient alphas showed
high reliability (α>0.95) and consistency with minimal
measurement error for all nine items [28]. The BFI is
considered to be an acceptable subjective tool in the
measurement of cancer-related fatigue and it has been
validated in other languages for its use worldwide [16, 29].
2.3 Selection of covariates
The correlation between CRF and muscle mass/strength
was adjusted for the following variables: cancer type and
stage, prognosis, concurrent oncological treatments and
medications, laboratory parameters, presence and severity
of particular symptoms such as pain and depression,
performance status, presence of comorbidities, along with
information on isometric handgrip dynamometry, isokinetic
dynamometry of the knee extensors and on appendicular
lean mass. These variables were selected because they have
been found to be predictive for CRF in patients with
advanced cancer and were available in the HCCD [30]
For oncological treatments, we considered the presence or
absence of concurrent chemotherapy and/or radiotherapy. For
medications potentially impacting on fatigue, we have
considered the presence or absence of at least one of the
following medications: statins, anti-inflammatories (both
steroidal and non-steroidal), ACE inhibitors, anti-hormonal
agents, anti-oxidants, essential amino acids, anabolic hor-
mones, and metformin. Patient’s prognosis was classified
according to the presence/absence of death within 8 weeks
from the time of assessment. For laboratory values, we have
examined the presence or absence of high CRP (>5 g/dL),
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recommended by Evans et al. [10]. The presence and severity
of symptoms experienced at the time of patient enrollment
were measured by the Edmonton Symptom Assessment Scale
(ESAS) [31]. The ESAS consists of nine visual analogue
scales for measuring pain, shortness of breath, nausea,
depression, activity, anxiety, well-being, drowsiness, and
appetite. Concurrent diseases were measured using the
Charlson comorbidity score [32]. This score ranges from 0
to a maximum of 33 and is based on the presence of certain
diseases with assigned values or weights. We developed an
adjusted Charlson score, which excluded the diagnosis of
cancer, since our intention was to measure conditions other
than the patient’s principal diagnosis. Performance status was
measured according to the Eastern Cooperative Oncology
Group scale [33]. Variables were examined in the continuous
and categorical form. The cutoff points for the latter were
chosen according to Evans et al. [10], as well as distribution
of cases, clinical meaningfulness and biologic plausibility.
2.4 Statistical analysis
Both univariate and multivariate linear regression analyses
were used to test the relationships between the following
variables: (1) handgrip strength (HGS), (2) quadriceps
strength (QS) and (3) SMMI, and BFI (dependent variable).
Multivariate models were implemented in three stages.
First, we created three separate linear regression models
where the relationships between BFI and HGS, QS and
SMMI respectively were adjusted for age, sex, type of
cancer and prognosis. Next, all independent variables
selected from the HCCD were added one at a time, to the
latter models to detect any significant contribution. Finally,
any interaction terms among the best set of variables
identified were also tested in the final three models.
All statistical analyses were performed using SPSS
(version 14.0, Chicago, USA).
3 Results
A total of eighty-four patients (48 men and 36 women) with a
mean age (SD) of 61.6 (±13.2)years were selected retrospec-
tively for this study (Tables 1 and 2). Patients with metastatic
gastrointestinal malignancies were more prevalent in the
study sample. In general, their performance status was fair,
they had low comorbidity burden and they were not
undergoing concurrent oncological treatments. However,
Variables Mean±SD B 95% CI
n (%)
Age (years) 61.6±13.2 0.02 −0.36 to 0.40
Sex Female 36 (42.8) 0.9 −9.1 to 11.0
Male 48 (57.2) 1
BMI (kg/m
2) 24.1±5.4 −1.6** −2.4 to −0.7
Tumor type NSCLC 16.0 (19.0) −0.8 −13.5 to 11.9
GI 68 (81.0) 1
Cancer stage Metastatic 48 (57.0) −4.9 −7.7 to 14.9
Locally Advanced 36 (43.0) 1
Chemotherapy Yes 22 (26.2) 3.6 −7.7 to 14.9
No 62 (74.8) 1
Radiotherapy Yes 11 (13.1) 0.1 −14.7 to 14.9
No 73 (87.9) 1
Medications impacting
on CRF
Yes 29 (34.5) 1.7 −9.0 to 12.5
No 52 (61.9) 1
Hemoglobin <119 g/dL 27 (32.1) 12.0*** 1.6 to 22.4
≥120 g/dL 56 (66.7) 1
Albumin <32 g/dL 11 (13.1) 23.4** 9.4 to 37.3
≥32 g/dL 73 (85.7) 1
C-reactive protein >5 g/dL 54 (64.3) 5.6 −7.0 to 14.2
≤5 g/dL 28 (33.3) 1
ECOG performance status 1.22±0.9 16.1* 12.1 to 20.0
Charlson comorbidity index 0.6±1.3 0.08 −3.8 to 3.9
Pain (0–10; 10 worst) 3.3±2.8 2.6* 1.2 to 4.1
Depression (0–10; 10 worst) 3.3±2.7 2.9** 1.2 to 4.6
Table 1 Patient demographics
and clinical characteristics:
summary of the bivariate linear
regression; fatigue level (BFI)
is the dependent variable
BMI body mass index, NSCLC
non-small cell lung cancer, GI
gastrointestinal, ECOG Eastern
Cooperative Oncology Group
*p<0.001; **p<0.01;
***p<0.05
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potentially impacting on CRF. Univariate linear regression
analysis showed BFI to be significantly associated with body
mass index, weight loss, anemia, hypoalbuminemia, activity
level, pain, depression, and sarcopenia along with SMMI,
HGS, and QS (Tables 1 and 2). There were no correlations
between muscle quality and fatigue (Table 2).
HGS (r=−0.34; p=0.018), QS (r=−0.39; p=0.024) and
SMMI (r=−0.60; p<0.001) were negatively correlated with
BFI total scores in men but not in women (Figs. 1, 2,a n d3).
Multivariate linear regression analyses revealed that HGS
(Table 3), QS (Table 4), and SMMI (Table 5)w e r e
negatively correlated with BFI. There was a significant
interaction between SMMI and sex (Table 5) indicating that
BFI decreased with increasing SMMI in men, but that BFI
did not change with SMMI in women (Fig. 3). There were
no interactions between sex and HGS (Table 3)o rQ S
(Table 4).
Age, diagnosis, (lung vs. gastrointestinal tumor) and
prognosis had no significant impact on CRF, whereas pain,
depression, malnutrition, and concurrent chemotherapy did
in most multivariate models. Performance status could not
be included in the multivariate models because of collinearity
issues.
Table 2 Body composition, muscle strength and muscle quality: summary of the bivariate analysis, fatigue level (BFI) is the dependent variable
Variables Mean±SD B 95% CI
Arm lean mass (kg) 2.37±0.77 −0.004*** −0.007 to −0.001
Leg lean mass (kg) 7.41±1.79 −0.001*** −0.003 to −0.001
SMMI (kg/m) −4.8** −8.4 to −1.3
Sarcopenia
a Yes 11.4** 1.3–21.4
No 1
Handgrip strength (kg) 30.0±10.4 −0.6*** −1.1 to −0.15
Quadriceps strength (Nm) 76.1±46.7 −0.1*** −0.2 to −0.01
(n=57)
b
HGS muscle quality
c 12.7±2.5 −0.6 −2.6 to 1.4
QS muscle quality
d 10.0±4.5 −1.2 −2.5 to 0.03
(n=57)
SMMI skeletal muscle mass index
*p<0.001; **p<0.01; ***p<0.05
aSarcopenia was calculated using the male (<7.26 kg of appendicular [arm+leg] skeletal muscle mass/ht
2) and female (<5.45 kg of appendicular
[arm+leg] skeletal muscle mass/ht
2) cutoffs as determined by Baumgartner et al. [41]
b57/84 patients were tested for quadriceps strength using the BIODEX; Nm newton-meters
cHandgrip muscle quality=kg force/kg dominant arm mass
dQuadriceps muscle quality=Nm torque/kg dominant leg mass
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Fig. 1 Correlation between isometric handgrip strength (HGS) and the
Brief Fatigue Inventory (BFI) in male (dotted line, n=48) and female
(solid line, n=36) patients with newly diagnosed advanced cancer
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Fig. 2 Correlation between isokinetic (60°/s) quadriceps extension
strength (QS) and the Brief Fatigue Inventory (BFI) in male (dotted
line, n=33) and female (solid line, n=24) patients with newly
diagnosed advanced cancer
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In the present study, lower levels of HGS and QS were both
found to be associated with higher levels of CRF in patients
with advanced gastrointestinal and non-small cell lung
cancers while adjusting for other independent predictors of
CRF in this patient population. We identified both upper
and lower body muscle strength as significant predictors of
CRF. Similar correlations between isometric handgrip
strength and fatigue have been observed with some [11,
13] but not all [12, 23] cancer diagnoses. An explanation
for this apparent lack of consistency as a result of
multivariate regression analyses may be due to the fact
that handgrip strength exerts a minimal role with increasing
levels of fatigue severity [23]. The relation between lower
limb strength development and fatigue has received very
little attention. To date, two studies have assessed quadri-
ceps leg strength directly in cancer patients [26, 27];
however, neither study incorporated any subjective fatigue
measure. Although there appears to be a paucity of published
reports investigating the relationship between direct measures
of leg strength and fatigue in different cancer populations,
there have been reports showing a significant association
between cancer-related fatigue and the 30-s timed sit-to-stand
test [13, 23]. This functional test is considered to be an
indirect but reliable performance measure of combined leg
strength and endurance. Considering the obvious contribu-
tion of the quadriceps muscle group to the wide variety of
subjective tests (e.g., sit-to-stand test, timed up and go, and
the 6-min walk test) used to assess functional performance in
the cancer patient, there clearly is a need to determine the
role and importance of lower limb strength as an independent
variable in this relationship.
With respect to SMMI, we did observe a significant
univariate correlation with CRF. However, when we
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Fig. 3 Correlation between skeletal muscle mass index (SMMI) and
the Brief Fatigue Inventory (BFI) in male (dotted line, n=48) and
female (solid line, n=36) patients with newly diagnosed advanced
cancer
Table 3 Association of isometric handgrip strength and fatigue levels
(BFI) in advanced cancer patients: final multivariate regression model
Variables R square: 0.51
B 95% CI
Intercept 57.7** 16.8–98.7
HGS (kg) −0.9** −1.5 to −0.3
Sex (male 0, female 1) −17.0** −29.6 to −4.5
Weight loss (≤5%=0, >5%=1) 8.7*** 0.6–16.8
Albumin (≥3.2 g/dL=0, <3.2 g/dL=1) 21.3** 8.8–33.9
Depression (0–10; 10 worst) 2.3** 0.7–3.8
Pain (0–10; 10 worst) 2.6** 1.2–4.1
Concurrent chemotherapy (no=0, yes 1) 10.5*** 1.5–19.5
HGS handgrip strength, B is the unstandardized regression coefficient,
95% CI confidence interval
*p<0.001; **p<0.01; ***p<0.05
Table 4 Association of isokinetic quadriceps extensor strength and
fatigue levels (BFI) in advanced cancer patients: final multivariate
regression model
Variables R square: 0.30
B 95% CI
Intercept 48.5*** 8.8–88.0
QS (Nm) −0.2*** −0.3 to −0.01
Pain (0–10; 10 worst) 2.7*** 0.7–4.8
QS quadriceps strength in newton-meters, B is the unstandardized
regression coefficient, 95% CI confidence interval
*p<0.001, **p<0.01, ***p<0.05
Table 5 Association of skeletal muscle mass index and sex on fatigue
levels (BFI) in advanced cancer patients: final multivariate regression
model
Variables R square: 0.46
B 95% CI
Intercept 81.4** 27.1–135.2
SMMI (kg/m) −7.5** −13.0 to −2.0
Sex (male=0, female=1) −80.0*** −142.0 to −18.1
SMMI×Sex 10.8*** 1.2–20.5
Albumin (≥3.2 g/dL=0, <3.2 g/dL=1) 21.0** 7.9–34.0
Depression (0–10; 10 worst) 1.8*** 0.2–3.4
Pain (0–10; 10 worst) 2.3** 0.8–3.9
SMMI skeletal muscle mass index as calculated by appendicular lean
mass/height
2, B is the unstandardized regression coefficient, 95% CI
confidence interval
*p<0.001; **p<0.01; ***p<0.05
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emerged between SMMI and sex and BFI scores. The BFI
scores were lower in males with higher SMMI while no
similar relationship existed in females. Thus, the results of
this study suggest that changes in muscle mass of females
are not at all related to changes in CRF. To unequivocally
state that there is a true sex-related difference in the relation
between muscle mass and CRF. The limited sample size in
the female group may have hindered the above relationship.
Furthermore, the fact that the overall clustering of values
for muscularity in men (e.g., 5.5–10.5 kg SMMI) versus
that found in women (e.g., 4.5–7.0 kg SMMI) may simply
be due to differences in BMI and circulating sex hormones.
Further studies need to be done in order to test this
hypothesis.
Fatigue has been shown to be related to indices of body
composition and anthropometric measurements [11–13]. In
elderly breast cancer survivors, higher fatigue scores were
related to elevated body fat [13]. Even though these authors
measured body composition using dual-energy X-ray
absorptiometry (DXA), it was unfortunate that there was
no report of the skeletal muscle mass measurement of the
leg which could have linked the SMMI with fatigue in this
group of patients. Stone et al. [11] found that mid-arm
circumference was significantly related to subjective meas-
ures of fatigue in patients with advanced forms of lung,
breast and prostate cancer. An earlier paper published from
the same laboratory using a similar subset of advanced
cancer patients showed no relationship between fatigue,
measures of muscle function (e.g., grip strength and grip
fatigue), and measures of body composition (e.g., BMI,
triceps skin-fold, and limb circumferences)[12]. Theuseofa
singlesitetriceps skin-foldand circumferential measure ofthe
mid-armareaisonlyagrossestimateoflocalsubcutaneousfat
and overall arm mass, respectively. Neither limb skin-fold nor
circumference provides a direct and accurate assessment of
appendicular muscle mass. Thus, these measurement techni-
ques do not specifically assess the different tissue compart-
ments of the limb. This lack of measurement precision and
accuracy could partially explain the discrepancies found
between our study and others [12, 23]. Although not as
accurate as magnetic resonance imaging and computed
tomography, DXA is a valid assessment technique of body
composition that has been shown to be highly reliable in
detecting whole body and segmental measurements of
skeletal muscle mass [20, 34, 35]. It has been the modality
of choice in aging studies [36–38] and we have shown that
the DXA is a precise instrument in the clinical assessment of
patients with advanced cancer [22].
When developing multivariate regression models to
determine the independent importance of key factors
and criteria of CRF, muscle strength as measured by
handgrip isometric performance has not generally been
shown to be a consistent or strong predictor of fatigue.
When Stone et al. [11] controlled for sex, age, diagnosis,
concomitant medical illnesses, symptom subscales (e.g.,
pain), psychological distress (e.g., dyspnea), mid-arm
circumference, and grip strength in their multiple linear
regression model, only dyspnea, pain and disease burden
were related to fatigue. Even though Brown et al. [23]
found that chair-rise times lengthened with increasing fatigue,
they reported no relationship when controlling for fatigue
severity, body composition (e.g., skin-fold and limb circum-
ference measurements), subjective weakness measured by a
visual analogue scale, or strength (e.g., handgrip) in advanced
lung cancer patients. However, based upon a stepwise
regression model, Winters-Stone et al., [13] found that in a
group of long-term breast cancer survivors, lower extremity
strength based upon the number of chair sit-to-stand
repetitions in 30 s, as well as self-reported physical activity
levels, and age were independent predictors of fatigue. The
discrepancies among the studies could be partially explained
by the variety of different tumor types in the studies as well
age and sex. These findings also highlight the multitude of
factors and complex interactions that are associated with
CRF.
In addition to the independent associations of skeletal
muscle mass and strength, our multiple regression models
uncovered several other significant and independent corre-
lates of CRF such as weight loss, low albumin levels,
depression, prior chemotherapy treatment, and pain. These
are all factors that have been frequency linked with fatigue
[6, 9]. Thus, the sheer number of independent associations
reinforces the difficulty in understanding the pathogenesis
of CRF. Nevertheless, our study supports the need for an
interdisciplinary approach to the assessment and manage-
ment of CRF. This approach should include optimal
symptom control along with nutritional and exercise
interventions [30].
Despite this complex pathophysiology of CRF and the
fact that our study was cross-sectional with a single time
point measurement, we have established somewhat robust
independent relationships among muscle strength, mass,
and CRF in this cancer population. However, whether the
origin of CRF in this and other studies is related to
peripheral or central mechanisms remains to be determined.
A classic method to assess peripheral fatigue in cancer
patients is to compare the force output of the muscle with
electromyographic amplitudes and magnetic resonance
spectroscopy. In efforts to measure central influences and
what role it plays in CRF mechanisms, novel studies using
innovative techniques incorporating transcranial magnetic
stimulation and magnetic resonance imaging will link
cerebral motorneuronal activity with regional location. A
review of the peripheral and central mechanisms along with
a description of the research and clinical tools used to
J Cachexia Sarcopenia Muscle (2010) 1:177–185 183evaluate the possible physiological interactions identifying
CRF has been recently published by Davis and Walsh [39].
In summary, our study strongly supports an independent
association between muscle strength, mass, and CRF.
Future studies should confirm a cause–effect nature of this
association through a clinical trial by examining the effect
of nutritional and exercise interventions on CRF in patients
with advanced cancer. Optimal symptom control remains a
cornerstone in the treatment of CRF. Modern technology
should assist both researchers in better defining the
different pathophysiologic mechanisms of CRF and clini-
cians in personalizing the treatments of this important and
prevalent symptom in advanced cancer patients.
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